X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (78) 78
humans (68) 68
index medicus (68) 68
colorectal cancer (50) 50
colorectal neoplasms - drug therapy (42) 42
colorectal neoplasms - genetics (41) 41
female (38) 38
male (35) 35
cetuximab (34) 34
aged (31) 31
middle aged (31) 31
mutation (28) 28
cancer (27) 27
colorectal neoplasms - pathology (26) 26
metastasis (24) 24
adult (22) 22
panitumumab (21) 21
chemotherapy (20) 20
settore med/06 - oncologia medica (18) 18
drug resistance, neoplasm (17) 17
egfr (17) 17
antineoplastic agents - therapeutic use (16) 16
kras (16) 16
neoplasm metastasis (16) 16
therapy (15) 15
animals (14) 14
antibodies, monoclonal - therapeutic use (14) 14
gene copy number (14) 14
receptor, epidermal growth factor - antagonists & inhibitors (14) 14
research (14) 14
treatment outcome (14) 14
tumors (14) 14
article (13) 13
genetic aspects (13) 13
aged, 80 and over (12) 12
antineoplastic agents - pharmacology (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
mutations (12) 12
prognosis (12) 12
resistance (12) 12
analysis (11) 11
cell line, tumor (11) 11
drug resistance, neoplasm - genetics (11) 11
ras proteins - genetics (11) 11
1st-line treatment (10) 10
acquired-resistance (10) 10
beer (10) 10
biochemistry (10) 10
biomarkers (10) 10
chemistry (10) 10
compositions or test papers therefor (10) 10
condition-responsive control in microbiological orenzymological processes (10) 10
enzymology (10) 10
human necessities (10) 10
hygiene (10) 10
measuring or testing processes involving enzymes, nucleicacids or microorganisms (10) 10
medical or veterinary science (10) 10
metallurgy (10) 10
microbiology (10) 10
molecular targeted therapy (10) 10
mutation or genetic engineering (10) 10
organic chemistry (10) 10
peptides (10) 10
preparations for medical, dental, or toilet purposes (10) 10
processes of preparing such compositions (10) 10
proto-oncogene proteins p21 (10) 10
receptor, epidermal growth factor - genetics (10) 10
spirits (10) 10
vinegar (10) 10
wine (10) 10
amplification (9) 9
antibodies, monoclonal, humanized (9) 9
care and treatment (9) 9
colon-cancer (9) 9
colorectal carcinoma (9) 9
colorectal neoplasms - metabolism (9) 9
expression (9) 9
monoclonal antibodies (9) 9
patients (9) 9
proto-oncogene proteins - genetics (9) 9
cancer therapies (8) 8
carcinoma (8) 8
clinical trials (8) 8
drug resistance (8) 8
drug therapy (8) 8
gene expression regulation, neoplastic (8) 8
health aspects (8) 8
hematology, oncology and palliative medicine (8) 8
liquid biopsy (8) 8
metastases (8) 8
mice (8) 8
neoplasms (8) 8
proto-oncogene proteins b-raf - genetics (8) 8
antibodies, monoclonal - pharmacology (7) 7
braf (7) 7
digestive system diseases (7) 7
epidermal growth factor (7) 7
growth-factor receptor (7) 7
heterogeneity (7) 7
irinotecan (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. 738 - 746
Journal Article
Nature, ISSN 0028-0836, 10/2015, Volume 526, Issue 7572, pp. 263 - 267
Colorectal cancer is the third most common cancer worldwide, with 1.2 million patients diagnosed annually. In late-stage colorectal cancer, the most commonly... 
PANITUMUMAB | THERAPY | MULTIDISCIPLINARY SCIENCES | SEQUENCE | ACQUIRED-RESISTANCE | SOMATIC MUTATION | IDENTIFICATION | GENE COPY NUMBER | ACTIVATING MUTATIONS | BREAST | INSIGHTS | Receptor, Epidermal Growth Factor - genetics | Receptor, ErbB-2 - genetics | Proto-Oncogene Proteins p21(ras) - genetics | Colorectal Neoplasms - genetics | Genomics | Humans | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Molecular Targeted Therapy | Receptor, Fibroblast Growth Factor, Type 1 - genetics | MAP Kinase Kinase 1 - genetics | Colorectal Neoplasms - drug therapy | Female | Antineoplastic Agents - pharmacology | Insulin Receptor Substrate Proteins - genetics | Colorectal Neoplasms - metabolism | Antibodies, Monoclonal - pharmacology | Cetuximab - pharmacology | DNA Copy Number Variations - genetics | Mutation - genetics | Genome, Human - genetics | Receptor, Epidermal Growth Factor - chemistry | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Exome - genetics | Animals | Receptor, Platelet-Derived Growth Factor alpha - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice | Drug Resistance, Neoplasm - drug effects | Care and treatment | Gene mutations | Colorectal cancer | Drug metabolism | Genetic aspects | Identification and classification | Health aspects | Proteins | Epidermal growth factor | Genes | Clinical trials | Mutation | Kinases | Cancer therapies | Tumors
Journal Article
Nature, ISSN 0028-0836, 06/2012, Volume 486, Issue 7404, pp. 532 - 536
Journal Article
Nature Medicine, ISSN 1078-8956, 07/2015, Volume 21, Issue 7, pp. 795 - 801
Journal Article
Molecular Oncology, ISSN 1574-7891, 12/2014, Volume 8, Issue 8, pp. 1495 - 1507
Journal Article
Cancer Discovery, ISSN 2159-8274, 2013, Volume 3, Issue 6, pp. 658 - 673
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 10/2009, Volume 101, Issue 19, pp. 1308 - 1324
The monoclonal antibodies panitumumab and cetuximab that target the epidermal growth factor receptor (EGFR) have expanded the range of treatment options for... 
CELL LUNG-CANCER | PHASE-III TRIAL | TYROSINE KINASE INHIBITORS | COLON-CANCER | KRAS MUTATIONS | K-RAS MUTATIONS | PROGRESSION-FREE-SURVIVAL | ONCOLOGY | CETUXIMAB PLUS IRINOTECAN | IN-SITU HYBRIDIZATION | GENE COPY NUMBER | PTEN Phosphohydrolase - drug effects | Predictive Value of Tests | Proto-Oncogene Proteins p21(ras) - genetics | Colorectal Neoplasms - genetics | Humans | Antibodies, Monoclonal - therapeutic use | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | Colorectal Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - drug effects | Biomarkers, Tumor - metabolism | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Cetuximab | Odds Ratio | PTEN Phosphohydrolase - genetics | Proto-Oncogene Proteins - drug effects | Antibodies, Monoclonal - pharmacology | Proto-Oncogene Proteins - genetics | Randomized Controlled Trials as Topic | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Proto-Oncogene Proteins p21(ras) - drug effects | Animals | Class I Phosphatidylinositol 3-Kinases | Mutation - drug effects | Proto-Oncogene Proteins B-raf - drug effects | Proto-Oncogene Proteins B-raf - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Colorectal Neoplasms - pathology | Neoplasm Staging | Research Design | Usage | Care and treatment | Prognosis | Gene mutations | Colorectal cancer | Monoclonal antibodies | Development and progression | Genetic aspects | Research | Biological markers | Health aspects | Biomarkers | Oncology | Cancer therapies | Clinical outcomes | Review
Journal Article
Gut, ISSN 0017-5749, 11/2018, Volume 67, Issue 11, pp. 1995 - 2005
Journal Article